explore -WSS

explore

author：comprehensive 2025-09-05 18:33:18 - browse：6762

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Why Talkspace is targeting Medicare, a tricky market

WSS

Microsoft's Peter Lee: Generative AI could help doctors be more human

Why Talkspace is targeting Medicare, a tricky market

Restaurant meals are packed with calories, and we still keep eating them

Tuberculosis patients need more than just free medication

Fetal cell organoids grown from amniotic fluid, study finds

State of the Union pitch: Bigger Medicare drug price negotiations

explore

explore

explore

At least 13 dead in Texas as scorching temps continue

Trump used to be more articulate. What could explain the change?

BioMarin wins approval for gene therapy to treat hemophilia A

Fetal cell organoids grown from amniotic fluid, study finds

How to save PrEP access — and even expand it

Stem cell biologist probes earliest stages of human development

Moonlake's readout produced a cash windfall. Risks remain

Election results set back Medicaid expansion plans

BioMarin wins approval for gene therapy to treat hemophilia A

Many breast cancer patients receive more radiation than needed

entertainment

The untold story of TV’s first prescription drug ad

Restaurant meals are packed with calories, and we still keep eating them

Flash flood warnings continue for parts of Missouri, Illinois

Doctors are clamoring for more clarity on Paxlovid prescribing

Pennsylvania man bitten on the head by bear during attack in his garage

The public health thinking behind the CDC’s new Covid guidance

hotspot

leisure time

focus

knowledge